Beam Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Beam TherapeuticsDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 31.4% bzw. 14.3% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich zurückgehen um 11.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -71.5% betragen.
Wichtige Informationen
-12.2%
Wachstumsrate der Gewinne
-5.5%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 28.2% |
| Wachstumsrate der Einnahmen | -19.6% |
| Zukünftige Eigenkapitalrendite | -65.5% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 19 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 57 | -444 | -352 | -326 | 10 |
| 12/31/2025 | 57 | -416 | -345 | -324 | 15 |
| 12/31/2024 | 49 | -388 | -331 | -328 | 16 |
| 6/30/2024 | 353 | -143 | -153 | -137 | N/A |
| 3/31/2024 | 361 | -135 | -169 | -139 | N/A |
| 12/31/2023 | 378 | -133 | -183 | -149 | N/A |
| 9/30/2023 | 82 | -285 | -392 | -353 | N/A |
| 6/30/2023 | 80 | -327 | -380 | -338 | N/A |
| 3/31/2023 | 77 | -316 | -353 | -306 | N/A |
| 12/31/2022 | 61 | -289 | -26 | 23 | N/A |
| 9/30/2022 | 92 | -315 | 39 | 94 | N/A |
| 6/30/2022 | 77 | -234 | 123 | 171 | N/A |
| 3/31/2022 | 60 | -238 | 148 | 191 | N/A |
| 12/31/2021 | 52 | -371 | -113 | -66 | N/A |
| 9/30/2021 | 1 | -401 | -134 | -92 | N/A |
| 6/30/2021 | 0 | -408 | -155 | -117 | N/A |
| 3/31/2021 | 0 | -366 | -132 | -107 | N/A |
| 12/31/2020 | 0 | -196 | -112 | -96 | N/A |
| 9/30/2020 | 0 | -132 | -100 | -89 | N/A |
| 6/30/2020 | 0 | -119 | -94 | -85 | N/A |
| 3/31/2020 | 0 | -106 | -87 | -74 | N/A |
| 12/31/2019 | 0 | -91 | -85 | -72 | N/A |
| 9/30/2019 | 0 | -86 | -79 | -57 | N/A |
| 6/30/2019 | 0 | -134 | -70 | -50 | N/A |
| 3/31/2019 | N/A | -124 | -57 | -42 | N/A |
| 12/31/2018 | N/A | -117 | -33 | -20 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BEAM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: BEAM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: BEAM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: BEAMDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-31.4% pro Jahr).
Hohe Wachstumseinnahmen: BEAMDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-31.4% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BEAM wird voraussichtlich in 3 Jahren unrentabel sein.